구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-PD-1 monoclonal antibody (Anti-PD-1 monoclonal antibody) Shanghai Celfuture Biotech Co., Lt…·PD-1 136 trials·t½ 13 h |
|---|---|
Overview Program | Anti-PD-1 monoclonal antibody |
Overview Company | Shanghai Celfuture Biotech Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Colorectal Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | checkpoint inhibitor-induced 3M syndrome: a case report |
MoA Biomarker | PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells high |
PK/PD Half-life | 13 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells highlights immunotherapy-resistant features in NSCLC.. Understanding resistance to anti-programmed cell death protein 1 (PD-1) therapy is critical for developing reversal strategies. Although ectonucleotidase CD39 (ENTPD1) (CD39) + cluster of differentiation 8 (CD8) + T cells have been associat… |
Clinical Safety signal | Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells highlights immunotherapy-resistant features in NSCLC.. Understanding resistance to anti-programmed cell death protein 1 (PD-1) therapy is critical for developing reversal strategies. Although ectonucleotidase CD39 (ENTPD1) (CD39) + cluster of differentiation 8 (CD8) + T cells have been associat… |
Clinical Selected reported efficacy | ORR 33.3% |
Clinical Reported ORR | 33.3% |
Clinical Reported PFS | NA |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03294083 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03294083 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-PD-1 monoclonal antibody (Anti-PD-1 monoclonal antibody) Shanghai Celfuture Biotech Co., Lt…·PD-1 136 trials·t½ 13 h |
|---|---|
Overview Program | Anti-PD-1 monoclonal antibody |
Overview Company | Shanghai Celfuture Biotech Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Colorectal Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | checkpoint inhibitor-induced 3M syndrome: a case report |
MoA Biomarker | PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells high |
PK/PD Half-life | 13 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells highlights immunotherapy-resistant features in NSCLC.. Understanding resistance to anti-programmed cell death protein 1 (PD-1) therapy is critical for developing reversal strategies. Although ectonucleotidase CD39 (ENTPD1) (CD39) + cluster of differentiation 8 (CD8) + T cells have been associat… |
Clinical Safety signal | Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells highlights immunotherapy-resistant features in NSCLC.. Understanding resistance to anti-programmed cell death protein 1 (PD-1) therapy is critical for developing reversal strategies. Although ectonucleotidase CD39 (ENTPD1) (CD39) + cluster of differentiation 8 (CD8) + T cells have been associat… |
Clinical Selected reported efficacy | ORR 33.3% |
Clinical Reported ORR | 33.3% |
Clinical Reported PFS | NA |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03294083 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03294083 |
추천 비교
추천 비교